CLINICAL SIGNIFICATION OF MARKER OF NEOANGIOGENESIS PLACENTA GROWTH FACTOR PLGF IN HEART TRANSPLANT RECIPIENTS
https://doi.org/10.15825/1995-1191-2009-3-88-95
Abstract
In transplanted hearts, peri- and postoperative ischemic and alloimmune stimuli may be interpreted as inadequate tissue perfusion leading to activation of angiogenic signaling. Placenta growth factor (PLGF) is a marker of neoangiogenesis, belonge to vascular endothelial growth factors (VEGF) family. It has been shown that PLGF serum levels are elevated during acute rejection and decrease after immunosuppressive therapy in pediatric heart transplant recipients. The study was aimed to investigate clinical and prognostic significance of PLGF in heart transplant recipients. 34 patients (pts) (42,5 ± 8,5 years, 29 men and 5 women, 21 patient with dilated cardiomyopathy, 13 – with ischemic heart disease) underwent heart transplantation (HTx) and were examined before and after HTx. Our results showed that pretransplant PLGF is a marker of posttransplant cardiovascular risk. Revealing PLGF plasma level in recipients during the first year after HTx also has prognostic value concerning development of cardiovascular complications. In the remote terms (1–16 years) after HTx PLGF plasma levels were significantly higher in recipients with TxCAD than in recipients without TxCAD. These findings confirm participation of PLGF in damage of the transplanted heart vessels.
About the Authors
О. P. Shevchenko
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Russian Federation
Russian Federation
O. V. Orlova
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Russian Federation
Russian Federation
S. El-Boustani
Russian Medical Academy Postgraduated Study, Moscow
Russian Federation
Russian Federation
E. N. Kаzakov
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Russian Federation
Russian Federation
A. J. Kormer
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Russian Federation
Russian Federation
References
1. Болезнь коронарных артерий пересаженного сердца / Под ред. академика В.И. Шумакова. М.: Медицинс- кое информационное агентство, 2008. 160 с.
2. Казаков Э.Н., Хубутия М.Ш., Кормер А.Я. Причины, ограничивающие длительное выживание пациентов с пересаженным сердцем // Вестник трансплантол. и искусственных органов. 2001. No 3–4. С. 29–32.
3. Трансплантация сердца / Под ред. В.И. Шумакова. М.: Медицинское информационное агентство, 2006. 400 с.
4. Шевченко А.О., Шевченко О.П., Орлова О.В., Тули- ков М.В. Неоангиогенез и коронарный атеросклероз: диагностическое значение нового биохимическо- го маркера – плацентарного фактора роста PLGF у больных ИБС // Кардиология. 2006. No 11. С. 9–145.
5. Шевченко А.О., Шевченко О.П., Эль-Бустани С., Князев А.Н. Маркер неоартериогенеза PLGF корел- лирует с толщиной комплекса интима–медиа общей сонной артерии и отдаленным прогнозом у больных ИБС // Кардиоваскулярная терапия и профилактика. 2007. No 6 (5). С. 340–341.
6. Шевченко О.П., Орлова О.В., Казаков Э.Н. и др. Кли- ническое значение ассоциированного с беременнос- тью протеина плазмы А (PAPP-A) при васкулопатии трансплантированного сердца // Вестник трансплан- тол. и искусственных органов. 2008. No 5. С. 23–28.
7. Шевченко О.П., Орлова О.В., Казаков Э.Н. и др. Кли- ническое значение растворимого лиганда CD40 у ре- ципиентов сердца // Вестник трансплантол. и искус- ственных органов. 2009. No 1. С. 40–45.
8. Apple F.S., Wu A.H., Mair J. et al. Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome // Clinical Chemistry. 2005. Vol. 51. P. 810–824.
9. Bjorndahl M., Cao R., Eriksson A., Cao Y. Blockage of VEGF-Induced Angiogenesis by Preventing VEGF Secretion // Circ Res. 2004. Vol. 94. P. 1443–1450.
10. Celletti F.L., Waugh J.M., Amabile P.G. et al. Vascular en- dothelial growth factor enhances atherosclerotic plaque progression // Nat. Med. 2001. Vol. 7. P. 425–429.
11. Fuchs D., Gruber A., Murr C. et al. Use of neopterin for the monitoring of cell-mediated immune response in vivo // Faist E., Bauer A.E., Schildberg F.W. (Eds.) The immune consequences of trauma, shock and sepsis. Mechanisms and therapeutic approaches. Lengerich, Pabst Science Publishers. 1996. Vol. 2.1. Р. 144–150.
12. Heeschen C., Dimmeler S., Fichtlscherer S. et al. Prognostic value of placental growth factor in patients
13. with acute chest pain. JAMA. 2004. Vol. 291. P. 435–
14.
15. Khurana R., Simons M., Martin J.F., Zachary I.C. Role
16. of angiogenesis in cardiovascular disease: a critical
17. appraisal // Circulation. 2005. Vol. 112. P. 1813–1824.
18. Khurana R., Moons L., Shafi S. et al. Placental growth factor (PLGF) promotes atherosclerotic intimal thicke- ning and macrophage accumulation // Circulation. 2005.
19. Vol. 111. P. 2828–2836.
20. Luttun A., Tjwa M., Moons L. et al. Revascularization of
21. ischemic tissues by PLGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti- Flt1 // Nat. Med. 2002. Vol. 8. P. 831–840.
22. Moreno P.R., Purushothaman K.R., Fuster V. et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability // Circulation. 2004. Vol. 110. P. 2032–2038.
23. Moulton K.S., Heller E., Konerding M.A. et al. Angio- genesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice // Circulation. 1999. Vol. 99. P. 1726– 1732.
24. Moulton K.S., Vakili K., Zurakowski D. et al. Inhibition of plaque neovascularization reduces macrophage accu- mulation and progression of advanced atherosclerosis // Proc. Natl. Acad. Sci USA. 2003. Vol. 100. P. 4736– 4741.
25. Pontrelli P., Ursi M., Ranieri E. et al. CD40L proin- flammatory and profibrotic effects on proximal tubular epithelial cells: role of NF-kB and Lyn // JASN. 2006. Vol. 17. P. 627–636.
26. Selvaraj S.K., Giri R.K., Perelman N. et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor // Blood. 2003. Vol. 102. P. 1515.
27. Shevchenko O.P., Shevchenko A.O., Orlova O.V. et al. Circulating Placenta Growth Factor Predicts Event-Free Survival in Coronary Artery Disease Patients // Arterio- scler. Thromb. Vasc. Biol. 2006. Vol. 26. P. 53–57.
28. Simons M. Angiogenesis: Where Do We Stand Now? // Circulation. 2005. Vol. 111. P. 1556–1566.
29. Taylor D.O., Yowell R.L., Kfoury A.G. et al. Allograft coronary artery disease: clinical correlations with circu- lating anti-HLA antibodies and the immunopathologic pattern of vascular rejection // J. Heart Lung. Transp. 2000. Vol. 70. P. 518.
30. Tjwa M., Luttun A., Autiero M., Carmeliet P. VEGF and PLGF: two pleiotropic growth factors with distinct roles in development and homeostasis // Cell Tissue Res. 2003. Vol. 314. P. 5–14.
31. Virmani R., Kolodgie F.D., Burke A.P. et al. Atherosclero- tic Plaque Progression and Vulnerability to Rupture: Angiogenesis as a Source of Intraplaque Hemorrhage // Arterioscler. Thromb. Vasc. Biol. 2005. Vol. 25. P. 2054– 2061.
Review
For citations:
Shevchenko О.P., Orlova O.V., El-Boustani S., Kаzakov E.N., Kormer A.J. CLINICAL SIGNIFICATION OF MARKER OF NEOANGIOGENESIS PLACENTA GROWTH FACTOR PLGF IN HEART TRANSPLANT RECIPIENTS. Russian Journal of Transplantology and Artificial Organs. 2009;11(3):88-95. (In Russ.) https://doi.org/10.15825/1995-1191-2009-3-88-95
Views:
1120
Email this article 